{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:00:51Z","timestamp":1779217251330,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41440-019-0244-4","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T23:10:31Z","timestamp":1554419431000},"page":"817-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism"],"prefix":"10.1038","volume":"42","author":[{"given":"Minoru","family":"Satoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Maruhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"244_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007;66:607\u201318.","journal-title":"Clin Endocrinol"},{"key":"244_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1470320310391329","volume":"12","author":"CC Kuo","year":"2011","unstructured":"Kuo CC, Wu VC, Huang KH, Wang SM, Chang CC, Lu CC, et al. Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group). J Renin Angiotensin Aldosterone Syst. 2011;12:348\u201357.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"244_CR3","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"244_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80\u20135.","journal-title":"Arch Intern Med"},{"key":"244_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"244_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension. 2012;60:618\u201324.","journal-title":"Hypertension"},{"key":"244_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1507\/endocrj.EJ13-0353","volume":"61","author":"Y Miyake","year":"2014","unstructured":"Miyake Y, Tanaka K, Nishikawa T, Naruse M, Takayanagi R, Sasano H, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61:35\u201340.","journal-title":"Endocr J"},{"key":"244_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530\u20137.","journal-title":"Hypertension"},{"key":"244_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"244_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00268-017-4311-1","volume":"42","author":"BS Miller","year":"2018","unstructured":"Miller BS, Turcu AF, Nanba AT, Hughes DT, Cohen MS, Gauger PG, et al. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the Primary Aldosteronism Surgical Outcome (PASO) classification system. World J Surg. 2018;42:453\u201363.","journal-title":"World J Surg"},{"key":"244_CR11","doi-asserted-by":"crossref","unstructured":"Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, et al. Long term outcome of Aldosteronism after target treatments. Sci Rep. 2016;6:32103.","DOI":"10.1038\/srep32103"},{"key":"244_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension. 2018;71:585\u201391.","journal-title":"Hypertension"},{"key":"244_CR13","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"244_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/bjs.9744","volume":"102","author":"A Muth","year":"2015","unstructured":"Muth A, Ragnarsson O, Johannsson G, Wangberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg. 2015;102:307\u201317.","journal-title":"Br J Surg"},{"key":"244_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1067\/mje.2002.120202","volume":"15","author":"MA Quinones","year":"2002","unstructured":"Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA.Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of EchocardiographyRecommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15:167\u201384.","journal-title":"J Am Soc Echocardiogr"},{"key":"244_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"244_CR17","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"244_CR18","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jpsychires.2012.08.025","volume":"46","author":"HE Kunzel","year":"2012","unstructured":"Kunzel HE, Apostolopoulou K, Pallauf A, Gerum S, Merkle K, Schulz S, et al. Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. J Psychiatr Res. 2012;46:1650\u20134.","journal-title":"J Psychiatr Res"},{"key":"244_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","volume":"25","author":"G Giacchetti","year":"2007","unstructured":"Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177\u201386.","journal-title":"J Hypertens"},{"key":"244_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911\u20138.","journal-title":"Hypertension"},{"key":"244_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62\u20139.","journal-title":"Hypertension"},{"key":"244_CR22","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/1470320314549220","volume":"16","author":"T Indra","year":"2015","unstructured":"Indra T, Holaj R, Strauch B, Rosa J, Petrak O, Somloova Z, et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst. 2015;16:1109\u201317.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"244_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","volume":"29","author":"VC Wu","year":"2011","unstructured":"Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011;29:1778\u201386.","journal-title":"J Hypertens"},{"key":"244_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/s-0032-1301902","volume":"44","author":"C Catena","year":"2012","unstructured":"Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res. 2012;44:188\u201393.","journal-title":"Horm Metab Res"},{"key":"244_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","volume":"168","author":"V Fourkiotis","year":"2013","unstructured":"Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol. 2013;168:75\u201381.","journal-title":"Eur J Endocrinol"},{"key":"244_CR26","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y Iwakura","year":"2014","unstructured":"Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocr Metab. 2014;99:1593\u20138.","journal-title":"J Clin Endocr Metab"},{"key":"244_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/HJH.0000000000000464","volume":"33","author":"R Holaj","year":"2015","unstructured":"Holaj R, Rosa J, Zelinka T, Strauch B, Petrak O, Indra T, et al. Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. J Hypertens. 2015;33:874\u201382.","journal-title":"J Hypertens"},{"key":"244_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1507\/endocrj.EJ16-0530","volume":"64","author":"KS Park","year":"2017","unstructured":"Park KS, Kim JH, Yang YS, Hong AR, Lee DH, Moon MK, et al. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism. Endocr J. 2017;64:623\u201332.","journal-title":"Endocr J"},{"key":"244_CR29","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1210\/jc.2008-2245","volume":"94","author":"LA Sechi","year":"2009","unstructured":"Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocr Metab. 2009;94:1191\u20137.","journal-title":"J Clin Endocr Metab"},{"key":"244_CR30","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocr Metab. 2011;96:2904\u201311.","journal-title":"J Clin Endocr Metab"},{"key":"244_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"244_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ando.2016.01.010","volume":"77","author":"A Pechere-Bertschi","year":"2016","unstructured":"Pechere-Bertschi A, Herpin D, Lefebvre H. SFE\/SFHTA\/AFCE consensus on primary aldosteronism, part 7: medical treatment of primary aldosteronism. Ann Endocrinol. 2016;77:226\u201334.","journal-title":"Ann Endocrinol"},{"key":"244_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Task Force Committee on Primary Aldosteronism TJES. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J. 2011;58:711\u201321.","journal-title":"Endocr J"},{"key":"244_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"244_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ando.2016.05.001","volume":"77","author":"L Amar","year":"2016","unstructured":"Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, et al. SFE\/SFHTA\/AFCE primary aldosteronism consensus: Introduction and handbook. Ann Endocrinol. 2016;77:179\u201386.","journal-title":"Ann Endocrinol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0244-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0244-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:31Z","timestamp":1684617631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0244-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1038\/s41440-019-0244-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"22 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}